Indeed, in experimental HNSCC mouse models, intrarumoral injection of TLR7 and TLR9 agonists in combination with PD-1 blockade led to an increase of M1/M2 macrophage ratio, prompted the recruitment of CTLs and resulted in tumor regression [62]. The gene discussed is TLR9; the disease is head and neck squamous cell carcinoma.